DBV Technologies S.A. (NASDAQ:DBVT) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of DBV Technologies S.A. (NASDAQ:DBVT) have received a consensus recommendation of “Moderate Buy” from the ten brokerages that are presently covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating, five have assigned a buy rating and two have assigned a strong buy rating to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $35.3750.

Several research analysts have recently commented on DBVT shares. Wall Street Zen lowered DBV Technologies from a “hold” rating to a “sell” rating in a report on Saturday, January 31st. Weiss Ratings reissued a “sell (e+)” rating on shares of DBV Technologies in a report on Monday, December 29th. Citizens Jmp lifted their price objective on shares of DBV Technologies from $21.00 to $45.00 and gave the stock a “market outperform” rating in a report on Wednesday, December 17th. Citigroup reissued an “outperform” rating on shares of DBV Technologies in a research note on Wednesday, December 17th. Finally, HC Wainwright set a $40.00 price target on DBV Technologies in a research report on Thursday, December 18th.

Insider Buying and Selling at DBV Technologies

In related news, major shareholder Bpifrance Epic sold 2,076,990 shares of the business’s stock in a transaction that occurred on Wednesday, December 17th. The stock was sold at an average price of $4.85, for a total value of $10,073,401.50. Following the completion of the sale, the insider owned 8,595,472 shares in the company, valued at $41,688,039.20. The trade was a 19.46% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Over the last 90 days, insiders sold 3,369,627 shares of company stock worth $15,489,908. Company insiders own 1.44% of the company’s stock.

Institutional Investors Weigh In On DBV Technologies

A number of hedge funds have recently made changes to their positions in the business. Allworth Financial LP bought a new position in shares of DBV Technologies during the 4th quarter valued at $32,000. UBS Group AG boosted its position in DBV Technologies by 165,347.3% during the fourth quarter. UBS Group AG now owns 244,862 shares of the company’s stock valued at $4,694,000 after buying an additional 244,714 shares during the period. GAMMA Investing LLC grew its stake in shares of DBV Technologies by 38.4% during the fourth quarter. GAMMA Investing LLC now owns 2,680 shares of the company’s stock valued at $51,000 after buying an additional 744 shares during the last quarter. Millennium Management LLC increased its holdings in shares of DBV Technologies by 26.1% in the third quarter. Millennium Management LLC now owns 337,863 shares of the company’s stock worth $3,379,000 after buying an additional 69,849 shares during the period. Finally, Citadel Advisors LLC bought a new stake in shares of DBV Technologies in the 3rd quarter valued at about $220,000. 71.74% of the stock is currently owned by institutional investors.

DBV Technologies Stock Performance

NASDAQ:DBVT opened at $21.26 on Friday. DBV Technologies has a 52-week low of $3.82 and a 52-week high of $26.18. The stock has a fifty day moving average of $19.35 and a 200 day moving average of $14.39. The firm has a market capitalization of $853.80 million, a price-to-earnings ratio of -4.11 and a beta of -0.98.

DBV Technologies Company Profile

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.